Research Article
Treatment Adherence among HIV and TB Patients Using Single and Double Way Mobile Phone Text Messages: A Randomized Controlled Trial
Table 2
Clinical characteristics of HIV and TB participants on treatment in the Buea and Kumba Hospitals.
| | Clinical characteristics | HIV | TB | | No (%) | No (%) |
| | Treatment regimen | TeLe | 185 (88.10) | — | | TeLeNev | 3 (1.43) | — | | ZiLNev | 8 (3.81) | | | TeL + PI | 11 (5.24) | — | | Dou + EFV | 3 (1.43) | — | | Total | 210 (100) | |
| | Duration on HAART (Months) | 1–7 | 159 (75.7) | — | | >7 | 51 (24.29) | — | | Total | 210 (100) | |
| | Duration on TB treatment (Months) | 1-3 | — | 63 (75.0) | | 4 | — | 21 (25.0) | | Total | | 84 (100) |
| | Co-infection with TB | No | 210 (100) | — | | Yes | 0 (0) | — | | Total | 210 (100) | |
| | Co-infection with HIV | No | — | 46 (54.8) | | Yes | — | 38 (45.2) | | Total | | 84 (100) |
| | Other diseases (malaria, intestinal parasitic infections | No | 201 (95.71) | 56 (66.7) | | Yes | 9 (4.29) | 28 (33.3) | | Total | 210 (100) | 84 (100) |
|
|
Key: Tele: tenofovir, lamivudine, efavirenz; TelNev: tenofovir, lamivudine, nevirapine; ZiLNev: zidovudine, lamivudine, nevirapine; TeL + PI: tenofovir, lamivudine + protein inhibitor; Dou + EFV; NCDs:non-communicable diseases.
|
